Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-center, placebo-controlled, randomized, parallel group, dose-ranging study to assess the efficacy and safety of LX201 for prevention of corneal allograft rejection episodes and graft failure following penetrating keratoplasty with LX201 implantation in subjects who are at increased immunological risk.

Next Previous
Trial Profile

A multi-center, placebo-controlled, randomized, parallel group, dose-ranging study to assess the efficacy and safety of LX201 for prevention of corneal allograft rejection episodes and graft failure following penetrating keratoplasty with LX201 implantation in subjects who are at increased immunological risk.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Oct 2012

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciclosporin (Primary)
  • Indications Keratoplasty rejection
  • Focus Therapeutic Use
  • Acronyms LUCIDA

    • Most Recent Events

    • 31 Jul 2012 Planned number of patients changed from 175 to 350 as reported by European Clinical Trials Database record.
    • 10 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Sep 2007 The expected completion date for this trial is now 1 Jan 2009.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top